NATCO Pharma shares rise 4% on launch of Semaglutide injection; board to consider demerger next week

The stock was trading 2.60% higher at ₹962.40 per equity share as of 1:51 PM.

The scrip has gained 1% in the last week and 8% over the month. On a year-to-date basis, it has advanced about 9%.

While the stock hit a 52-week high of ₹1,059 on July 24, 2026, it touched a year’s low of ₹726.80 apiece on April 7, 2025.

NATCO to launch Semaglutide generic injection multi-dose vials in India

The announcement comes as Semaglutide, the active ingredient in weight-loss drugs like Ozempic and Wegovy, is set to expire on Saturday, March 21. The drug maker said that its product will be launched on Saturday, i.e., day 1 of expiry of the patent for Semaglutide.

NATCO received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in February of this year for multi-dose vials and pen device, based on the clinical comparison study, it stated in a regulatory filing.

The drug manufacturer said it plans to launch Semaglutide injection in the form of multi-dose vials in strengths of 2mg/1.5ml, 4mg/3ml, and 8mg/3ml under the brand names SEMANAT and SEMAFULL.

It further stated that the multi-dose vials will be launched at a market price of ₹1,290 per month for 2 mg/1.5ml and 4mg/3ml and at an MRP of ₹1,750 for 8mg/3ml.

It noted that the pen devices, which are expected to be launched in April, will be priced at ₹4,000, ₹4,200, and ₹4,500 per month for strengths 2mg/1.5ml, 4mg/3ml, and 8mg/3ml, respectively.

As per the filing, Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

“NATCO is the first company to offer Semaglutide in the vial dosage form. It is the most affordable GLP-1 currently in the Indian market, as it is approximately 70% cheaper in cost than the pen device and 90% cheaper than the price of the innovator’s brand,” the firm said.

The drug manufacturer highlighted that it is the first company to offer generic Semaglutide in multi-dose vials with customised syringes, adding that it is also offering the product to third parties for co-marketing.

“This will increase patient accessibility to the GLP-1 therapy and would help in long-term compliance for the patients,” it said.

Board to consider demerger

In a separate regulatory filing dated March 18, NATCO said that its board of directors is scheduled to meet next week on Tuesday, March 24, to consider the demerger of its agrochemicals division.

It stated that the board will mull, among other things, the scheme of arrangement for the demerger of its agrochemicals division on a going concern basis into its wholly owned subsidiary, Natco Crop Health Sciences Limited.